Clinical Omics – Products

Thermo Fisher Scientific has announced a new portfolio of hematology-oncology assays for the Ion Torrent Genexus System designed to enable a future in which turnaround times for next-generation sequencing results can be reduced to less than 24 hours.

The company has extended program benefits to oncology laboratories and fast-tracking access to comprehensive molecular profiling on the Genexus System.

Bruker has announced the release of the diaPASEF workflow, a novel data-independent acquisition (DIA) method, using overlapping windows in the ion mobility domain to trigger MS/MS

The collaboration with Thermo Fisher is in full alignment with Evosep’s vision to improve quality of life and patient care.

Thermo Fisher and Biognosys to develop industry-leading mass spectrometry-based workflows for the efficient analysis of proteins in complex biological matrices.

Thermo Fisher and NX Prenatal to develop clinical mass spectrometry-based workflows for monitoring
maternal and fetal health during pregnancy and evaluating risk of complications.

Thermo Fisher and NX Prenatal to develop clinical mass spectrometry-based workflows for monitoring
maternal and fetal health during pregnancy and evaluating risk of complications.

The next-generation sequencing-based solution screens across solid tumors.

Validated tissue bank and pre-collected immuno-oncology datasets speed up investigative research projects through to clinical development.

New, easy-to-use analytical detection system extracts meaningful data quickly from acquisition to analysis.